This article was originally published in The Gray Sheet
Signs a letter of intent to sell $2 mil. of its unregistered common stock to International Capital Partners, a Stamford, Connecticut- based firm that specializes in advising smaller-growth companies. Biopool plans to use proceeds from the financing "to pay down existing debt, for capital equipment and expenditures, to increase research and development, and to promote marketing efforts." The Ventura, California-based producer of test kits to assess and diagnose vascular system disorders expects to complete the financing by April 30.
You may also be interested in...
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.
While good clinical practice inspectors in the UK and the US collaborate on matters of common interest, they say that mutual recognition is simply not possible.